Objective-Inflammation occurs during the progression of abdominal aortic aneurysm (AAA). IL (interleukin)-33 is a pleiotropic cytokine with multiple immunomodulatory effects, yet its role in AAA remains unknown. Approach and Results-Immunoblot, immunohistochemistry, and immunofluorescent staining revealed increased expression in adventitia fibroblasts from mouse AAA lesions. Daily intraperitoneal administration of recombinant IL-33 or transgenic IL-33 expression ameliorated periaorta CaPO 4 injury-and aortic elastase exposure-induced AAA in mice, as demonstrated by blunted aortic expansion, reduced aortic wall elastica fragmentation, enhanced AAA lesion collagen deposition, attenuated T-cell and macrophage infiltration, reduced inflammatory cytokine production, skewed M2 macrophage polarization, and reduced lesion MMP (matrix metalloproteinase) expression and cell apoptosis. Flow cytometry analysis, immunostaining, and immunoblot analysis showed that exogenous IL-33 increased CD4 + Foxp3 + regulatory T cells in spleens, blood, and aortas in periaorta CaPO 4 -treated mice. Yet, ST2 deficiency muted these IL-33 activities. Regulatory T cells from IL-33-treated mice also showed significantly stronger activities in suppressing smooth muscle cell inflammatory cytokine and chemokine expression, macrophage MMP expression, and in increasing M2 macrophage polarization than those from vehicle-treated mice. In contrast, IL-33 failed to prevent AAA and lost its beneficial activities in CaPO 4 -treated mice after selective depletion of regulatory T cells. Conclusions-Together, this study established a role of IL-33 in protecting mice from AAA formation by enhancing ST2-dependent aortic and systemic regulatory T-cell expansion and their immunosuppressive activities. Visual Overview-An online visual overview is available for this article. Li et al
A bdominal aortic aneurysm (AAA) is a chronic vascular inflammatory disease with permanent dilations and destructive remodeling of the abdominal aorta, which leads to aortic rupture in elderly persons. 1 AAA pathophysiology is complicated and contains massive aortic tissue inflammatory response and ECM (extracellular matrix) degeneration. 2, 3 Aortic tissue inflammatory response is characterized by the infiltration of inflammatory cells and local expression of inflammatory cytokines and proteases. 4 Additionally, endothelial cells, smooth muscle cells (SMCs), and fibroblasts in the vasculature also produce proteases to destroy the medial elastica and aggravate the progression of AAA. 2, 5 Current therapeutic measures rely merely on invasive surgical repairs. 1, 6 Therefore, it is urgent to explore noninvasive possibilities for these patients.
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IL (interleukin)-33-a member of the IL-1 family-is constitutively expressed in endothelial and epithelial cells at barrier sites, and its expression is induced in infiltrated inflammatory cells at the site of inflammation. [7] [8] [9] As an alarmin, IL-33 is rapidly released from damaged or necrotic cells.
9 ST2-the receptor for IL-33-has 2 primary isoforms: the transmembrane isoform (ST2L) and the soluble isoform (sST2) that serves as a decoy receptor for IL-33.
10 ST2 is expressed on immune cells, including Th2 cell, activated Th1 cells, regulatory T cells (Tregs), and type 2 innate lymphoid cells. [10] [11] [12] [13] Through binding to ST2 on these cells, IL-33 serves pleiotropic functions in both adaptive and innate immunities. Accumulated evidence suggests an important role of IL-33 in regulating inflammatory responses. 9 It is involved in the pathogenesis of lung inflammation, 14, 15 intestinal inflammation, 12, 16 infectious diseases, 11, 17 cancer immunity, 18 autoimmune disorders, 19 and cardiovascular diseases. [20] [21] [22] In transverse aortic constriction-induced mouse heart failure, mechanical stress-induced cardiac hypertrophy, cardiac dysfunction, myocardium fibrosis and inflammation, and postinjury survival were all impaired in IL-33-deficient mice. 23 Similarly, IL-33 reduced angiotensin II-and phenylephrine-induced cardiomyocyte hypertrophy in mice by inhibiting I-κBα activity and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) nuclear binding activity. Soluble ST2 blocked the antihypertrophic activity of IL-33. 20 These studies tested a direct role of IL-33 in regulating cardiac hypertrophy. Recently, IL-33 was found in mouse aorta, where it played a protective role in atherosclerosis. 24 Yet, the role of IL-33 in AAA remains unknown.
In this study, we demonstrated that IL-33 was elevated in AAA lesions, and adventitial fibroblasts were the major source. Repletion or overexpression of IL-33 protected against AAA injury. We also showed that IL-33 induced ST2-dependent Treg expansion. IL-33 lost its AAA-protective activity in the absence of Tregs.
Materials and Methods
Data available on request from the authors.
Mice
Male C57BL/6J mice aged 10 to 12 weeks were purchased from the Model Animal Research Center of Nanjing University (Nanjing, China). IL-33 transgenic mice on a C57BL/6J background were kindly provided by Dr Rong Mu from the Department of Rheumatology and Immunology, Peking University Peoples Hospital (Beijing, China). ST2 −/− mice on a C57BL/6J background were obtained from Dr Andrew McKenzie (Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, United Kingdom). DEREG (depletion of Treg) transgenic mice on a C57BL/6J background were purchased from the Jackson Laboratory (Bar Harbor, ME). AAA incidence in female mice is much lower than that in male mice in all tested experimental AAA models. 25 Therefore, we used only male mice throughout this study. All animal studies were approved by the Animal Care and Utilization Committee of Huazhong University of Science and Technology. Experiments were conducted in accordance with the National Institutes of Health guidelines.
AAA Models
Calcium Phosphate (CaPO 4 ) Model AAA was induced by CaPO 4 in mice at the age of 10 to 12 weeks as described previously. 26 Briefly, mice were anaesthetized with ketamine (50 mg/kg −1 ) and pentobarbital sodium (50 mg/kg −1 ), and the infrarenal region of the abdominal aorta was isolated, and a small piece of gauze soaked in 0.5 M CaCl 2 was applied around the aorta. After 10 minutes, the gauze was replaced by another piece of PBS-soaked gauze for 5 minutes. Control mice were similarly treated with 0.5 M NaCl for 15 minutes. Sham-operated mice were used as experimental controls.
Elastase Model
AAA was induced by elastase exposure in mice at the age of 10 to 12 weeks as described previously. 27 After anesthesia, the aorta was isolated from the renal vein to the iliac bifurcation and was bathed in either 10 μL of 100% porcine pancreatic elastase (No. E1250; Sigma-Aldrich, St. Louis, MO) or heat-inactivated elastase (control) for 10 minutes. After elastase exposure, the incision was stitched with a 4-0 suture.
Mice were euthanized 7 (CaPO 4 model) or 14 days (elastase model) after the surgery, and the abdominal aorta was harvested and photographed (Nikon D7200) to determine its external diameter by using Image-Pro Plus computer-assisted image analysis software. The adventitial circumferences at the maximal expanded portion of the infrarenal aortas were quantified as the maximal abdominal aortic diameter. At least 3 measurements of the maximal expanded portion of the infrarenal aorta of each mouse were averaged before calculating the mean of each experimental group. AAA was defined as an aortic diameter increase by ≥50% (≥0.75 mm) compared with the sham-operated group (n=17; 0.50±0.02 mm).
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Treatment and Groups
For the measurement of IL-33 and ST2 expression from AAA lesions, C57BL/6J mice were randomly divided into 2 groups that were treated with CaPO 4 or NaCl (n=5 per group). To test the effect of IL-33 in CaPO 4 -induced AAA, mice were randomly divided into 5 groups: (1) C57BL/6J mice treated with the recombinant IL-33 (No. 34-8332-85; eBioscience, San Diego, CA; n=15); (2) C57BL/6J mice treated with vehicle (PBS; n=15), in which the mice were injected intraperitoneally with 1 μg of IL 33 diluted in PBS or PBS containing 0.5% BSA daily after the operation for 7 days; (3) IL-33 transgenic group (IL-33TG; n=13); (4) NTG (nontransgenic) group (n=13); and (5) Sham-operated group (n=17). To test the effect of IL-33 in elastase-induced AAA, mice were randomly divided into 3 groups: (1) C57BL/6J mice treated with the recombinant IL-33 (n=10); (2) C57BL/6J mice treated with vehicle (PBS; n=10), in which the mice were injected intraperitoneally with 2 μg of IL 33 diluted in PBS or PBS containing 0.5% BSA every 2 days after the operation for 14 days; and (3) C57BL/6J mice underwent the same procedure but with heat-inactivated elastase (n=5). To investigate the involvement of Tregs in IL-33-mediated protection against AAA, DEREG mice were randomly divided into 5 groups and subjected to CaPO 4 -induced AAA: (1) DEREG mice subjected to a sham operation (n=10); (2) DEREG mice subjected to the AAA model injected intraperitoneally with 200 μL PBS (n=8); (3) DEREG mice subjected to the AAA model injected intraperitoneally with 1 μg diphtheria toxin (DT; Merck, Germany; n=10); (4) DEREG mice subjected to the AAA model injected intraperitoneally with 1 μg IL-33 (n=8); and (5) DEREG mice subjected to the AAA model injected intraperitoneally 
Histology and Immunohistochemical Analyses
After the mice were euthanized, aortas from the ascending aorta to the bifurcation of the iliac artery were isolated. Whole aortas were harvested, fixed for 24 hours in 4% paraformaldehyde, cut at the site of maximal diameter, and embedded in paraffin for cross section preparation. Aortic sections (4 μm each) were collected serially from the proximal to the distal aorta. At least 10 sections were prepared and analyzed per mouse. Serial sections were analyzed using the elastica van Gieson staining kit according to the manufacturer's protocol (No. 115974; EMD Millipore, Burlington, MA) for elastin assessment. Elastin degradation was graded as (1) <25% degradation, (2) 25% to 50% degradation, (3) 50% to 75% degradation, or (4) >75% degradation. 3 Sirius Red staining was analyzed according to the manufacturer's protocol (No. 09400-10, 0.1% Sirius Red; Polysciences, Inc, Warrington, PA) and presented as percentage of positive area. Apoptotic cells in lesions were determined with the in situ apoptosis detection kit according to the manufacturer's instructions (No. ab206386; Abcam, Cambridge, MA) and presented as positive numbers per millimeter squared.
Serial paraffin sections were also used for immunostaining using the following primary antibodies: CD3, CD68, MMP (matrix metalloproteinase)-2, MMP-9, and IL-33 with detailed information listed in Table I in the online-only Data Supplement. Apoptotic cells in lesions were determined with the TUNEL apoptosis detection kit according to the manufacturer's instructions (No. ab206386; Abcam). We counted the number of IL-33-positive cells, CD68-positive macrophages, CD3-positive T cells, Foxp3-positive Tregs, and TUNELpositive apoptotic cells. MMP-2 and MMP-9 were quantified and presented as percentage of positive area. All staining were imaged under the OLYMPUS BX51 microscope. We randomly selected 5 mice from each experimental group for immunohistological analysis based on the availability. All examinations were conducted by 2 trained, independent observers blinded to the genotype and treatment. A mean value was determined from at least 4 sections from each animal.
For immunofluorescent staining, paraffin sections were permeabilized with 0.3% TritonX-100 in PBS for 5 minutes and blocked with 5% fetal bovine serum and 10% donkey serum in PBS at room temperature for 1 hour. Tissues were stained for 2 hours at room temperature in the presence of goat anti-IL-33, rabbit anti-vimentin, or rabbit anti-α-SMA (α-smooth muscle actin), followed by staining for 1 hour at room temperature with PE-donkey anti-goat secondary antibody, FITC-donkey anti-rabbit secondary antibody, or PE-Foxp3 (Table I in the online-only Data Supplement). Tissue sections were further stained with DAPI (4',6-diamidino-2-phenylindole) for 5 minutes before imaging (Nikon A1Si).
Cell Cultures
To examine the suppressive activity of IL-33-expanded Tregs in vitro, we isolated spleen CD4 
Flow Cytometry Analysis
To detect T-cell subsets in mice, mononuclear cells from the randomly selected spleen and blood were isolated by Ficoll density gradient (No. GE17-1440-02; Sigma-Aldrich). The cells were first stained with PE/Cy7-or APC-anti-CD4 and APC-anti-ST2 for 30 minutes and washed with PBS. Then, the cells were fixed, permeabilized, and stained with Alexa Fluor-anti-Ki67 and PE-anti-Foxp3 (Table I in the online-only Data Supplement). Other reagents used for flow cytometry are all listed in Table I in the online-only Data Supplement.
To determine IL-33-producing cells in AAA lesions, we sorted the CD45 + and CD45 − fractions from the digested aortas. Briefly, aortas were minced into small pieces and then digested in 1× Aorta Dissociation Enzyme Stock Solution (125 U/mL collagenase type XI, 60 U/mL hyaluronidase type I-s, 60 U/mL DNase1, and 450 U/mL collagenase type I; all enzymes were obtained from Sigma-Aldrich) at 37°C for 1 hour. Cell suspensions were prepared by filtering through a cell strainer (No. 322350, 70 µm size; BD Bioscience, Billerica, MA). 29 The harvested cells were labeled with FITC-anti-CD45 (Table  I in the online-only Data Supplement). Flow cytometry was performed using a FACS Calibur (BD Immunocytometry Systems, San Jose, CA). The results were analyzed using FlowJo 7.6.1 (TreeStar, Inc, Ashland, OR).
Western Blot
Equal amounts of total protein from tissues or cells were electrophoresed on 10% SDS (sodium dodecyl sulfate) polyacrylamide gels under a reducing condition and transferred to PVDF (polyvinylidene fluoride) membranes. After incubation in 5% nonfat milk for 2 hours at room temperature, membranes were incubated overnight at 4°C with the primary antibodies, including mouse anti-β-actin monoclonal antibody, rat anti-Foxp3 monoclonal antibody, goat anti-IL-33 polyclonal antibody, and rabbit anti-ST2 polyclonal antibody (Table  I in the online-only Data Supplement). Membranes were washed in tween-PBS and incubated with HRP-conjugated species-appropriate secondary antibodies (1:3000) for 2 hours at room temperature. An enhanced chemiluminescence kit (Pierce, Rockford, IL) was used to detect all protein bands, and β-actin was used as a housekeeping protein for analysis between groups.
Reverse Transcription Polymerase Chain Reaction
Total RNA was isolated from randomly selected aortas or cells using Trizol Isolation Reagent (No. 15596018; Invitrogen, Carlsbad, CA). Reverse transcription was performed using the PrimeScript RT Reagent Kit (No. RR064B; Takara Biotechnology, Dalian, China), and reverse transcription polymerase chain reaction (RT-PCR) was completed using the SYBR Green Master Mix (No. RR066A; Takara, Japan) on an ABI PRISM 7900 Sequence Detector System (Applied Biosystems, Foster City, CA). mRNA levels were standardized with GAPDH, and all experiments were completed in triplicates. The primers used for RT-PCR were listed in Table II in the online-only Data Supplement.
ELISA
The concentration of IL-33 in mouse plasma was analyzed using ELISA kits (No. 88-7333-22; eBioscience) according to the manufacturer's instructions. All samples were detected in duplicates.
Statistical Analysis
Data were presented as mean±SEM. To assess the statistical significance, Kolmogorov-Smirnov test with Lilliefors correction was first used to determine data normality. Equal variance between groups was tested by the F test. If evaluation of similar variances was passed, then Student t test was used for comparison between 2 groups. Nonparametric Mann-Whitney U test was used where data were not normally distributed. For comparisons among ≥3 groups, all data passed both normality and equal variance tests. A 1-way or 2-way ANOVA test plus a post hoc Bonferroni test was used. In all cases, statistical significance was concluded where the 2-tailed probability was <0.05. All analyses were performed using GraphPad Prism 6.0 and SPSS 18.0 software.
Results
IL-33 Is Upregulated in Experimental AAA
IL-33 is found in mouse aortas, 24 yet its expression in AAA lesions has not been tested. To determine the expression of IL-33 in AAAs, we produced CaPO 4 -induced AAA in mice. As reported previously, 26, 30 after perivascular application of PBS following CaCl 2 to the infrarenal abdominal aorta, the external aortic diameter increased by almost 2-fold at day 8 compared with NaCl-treated mice (data not shown). Proteolytic activation produced both the 20-and 18-kDa active forms of IL-33. 31 Immunoblot analysis demonstrated significantly increased production of both the 20-and 18-kDa active forms of IL-33 in CaPO 4 -induced AAA lesions relative to those in the aortic extracts from NaCl-treated mice ( Figure 1A and 1B), although AAA production did not significantly increase plasma IL-33 levels compared with those from NaCl-treated mice as determined by ELISA (data not shown). RT-PCR also demonstrated much higher IL-33 mRNA levels in AAA lesions from CaPO 4 -treated mice than that in aortas from NaCl-treated mice ( Figure 1C ). Immunoblot analysis also detected increased expression of IL-33 receptor ST2 in AAA lesions from CaPO 4 -treated mice than that from the control mice ( Figure 1D and 1E) . Immunostaining showed more IL-33-positive cells within the aortic wall in CaPO 4 -induced AAA mice than those in NaCl control mice ( Figure 1F and 1G). Endothelial cells, fibroblasts, SMCs, and infiltrated inflammatory cells are known to produce IL-33. 8 To determine the cell type(s) that produce IL-33 in AAA lesions, we sorted the CD45 + and CD45 − fractions from the digested aortas and quantified the mRNA levels by RT-PCR. In AAA lesions, CD45 − cells were the major cell population that expressed IL-33 ( Figure 1H ). This finding was confirmed by immunofluorescent double staining, by which the majority of the IL-33-positive cells were vimentin + and α-SMA − fibroblasts located at the adventitia ( Figure 1I ). Figure 2A and 2B) and had fewer elastica fragmentations and more collagen deposition than those from NTG mice ( Figure 2C and 2D) . Further, infiltration of CD3 + T cells and CD68 + macrophages and the expression of inflammatory cytokines and chemokines, such as IL-6 and MCP-1 (monocyte chemotactic protein-1), were also decreased in IL-33-treated or IL-33 transgenic mice ( Figure 3A through 3C) . Meanwhile, administration of IL-33 markedly elevated the expression of M2 macrophage markers Arg-1, CD206, and Fizz1 and reduced the expression of M1 macrophage markers iNOS (inducible NO synthase), CD86, and TNF-α (tumor necrosis factor-α) in aortic lesions ( Figure 3D) . 17, 32 Flow cytometry analysis confirmed the increase of CD206 As a potent Th2 cytokine, 34, 35 IL-33 administration may affect T-cell subset polarization, which also affects AAA development. 36, 37 To test this possibility, we performed RT-PCR analysis of AAA lesion tissue extract and found that IL-33 administration reduced lesion Th1 cytokine IFN (interferon)-γ and Th17 cytokine IL17 but increased lesion Th2 cytokine IL-4 ( Figure 
IL-33 Protects
IL-33 Induces ST2-Dependent Treg Expansion in AAA Mice
Prior studies demonstrated a protective role of Tregs in the formation and expansion of experimental AAAs. 38 + and CD45 − fractions from digested aortas (n=8 per group). I, Immunofluorescent costaining of IL-33 with fibroblast vimentin and smooth muscle cell α-SMA (α-smooth muscle actin) in AAA lesions. All sections were from CaPO 4 -induced AAA mice. Rabbit IgG was used as corresponding antibody isotype controls (scale bar=100 μm). Data are mean±SEM. *P<0.05 and **P<0.01, unpaired t test was used in B and E; Mann-Whitney U test was used in C, G, and H. the expression of these inflammatory molecules. Yet, Tregs from IL-33-treated mice showed much stronger activity in inhibiting SMC expression of MCP-1 and IL-6 than those from PBS-treated mice ( Figure 5A and 5B). In RAW264.7 macrophages, Tregs from PBS-treated mice reduced the expression of MMP-2, yet Tregs from IL-33-treated mice displayed significantly stronger activity in blunting the expressions of both MMP-2 and MMP-9 ( Figure 5C and  5D ). In macrophages, we also found that Tregs from IL-33-treated mice were more potent than those from PBS-treated mice in enhancing the expression of M2-related genes (Arg-1, CD206, and Fizz1; Figure 5E through 5G) and suppressing the expression of M1 markers (iNOS, CD86, and TNF-α; Figure 5H through 5J) . + and CD8 + T cells in DEREG mice, although such reductions did not reach statistic significance. 42, 43 We produced CaPO 4 -induced AAA in DEREG mice while mice were treated with and without DT and IL-33 ( Figure 6A ). Flow cytometry analysis showed that DT treatment depleted splenic and blood CD4 +
IL-33 Enhances Treg Immunosuppressive
Foxp3
+ Tregs irrespective of IL-33 administration (Figure VIIIA and VIIIB) . Although the difference in survival did not differ between AAA mice with and without DT treatment (data not shown), the aortic diameters in DT-treated AAA mice were significantly bigger than those without DT treatment. IL-33 treatment reduced CaPO 4 -induced AAA growth only in mice without DT treatment but not in DT-treated mice ( Figure 6B and 6C) . On depletion of Treg cells, the protective roles of IL-33 in suppressing aortic wall elastica fragmentation and in increased AAA lesion collagen deposition were both muted ( Figure 6D ). AAA lesion T-lymphocyte and macrophage infiltration ( Figure 7A and 7B), MMP-2 and MMP-9 expression, and TUNEL-positive apoptotic cell counts ( Figure IXA and IXB in the online-only Data Supplement) were also increased in DT-treated mice. IL-33 treatment reduced these AAA lesion variables only in mice without DT treatment but not in Treg-depleted mice. To test whether increased AAA lesion size and aortic tissue remodeling ( Figure 6 ) and lesion CD3 + T cells and CD68 + macrophages in DT-treated mice ( Figure 7) were because of altered systemic inflammatory responses because of Treg depletion, we measured splenic total CD4 + T cells, lymphocytes, and splenocytes. Besides reduced splenic CD4 + T cells as expected, 43 DT treatment did not affect total spenocytes, total lymphocytes ( Figure VIIIC in the online-only Data 
IL-33 Suppresses Elastase ExposureInduced AAA in Mice
To support our conclusion and to test further a role of IL-33 in suppressing AAA formation, we produced porcine pancreatic elastase exposure-induced AAA in mice. In this second model, IL-33 treatment also reduced the AAA lesion sizes, reduced aortic wall elastica fragmentation, and increased lesion collagen deposition ( Figure XA 
Discussion
Emerging evidence suggests that IL-33 plays a role in regulating immune responses and associated inflammatory diseases. 9 Recent studies demonstrated an increase of IL-33 in the vasculature of atherosclerosis-prone Apoe −/− mice, and IL-33 treatment reduced atherosclerosis in these mice by inducing a Th1-to-Th2 switch and oxidatively modified LDL (low-density lipoprotein) antibody production. 24 IL-33 has also been considered as a biomarker associated with the development of chronic heart failure and acute myocardial infarction. Administration of IL-33 reduced cardiac hypertrophy and myocardial fibrosis and improved cardiac function in transverse aortic constriction mouse models. 20, [22] [23] [24] 44, 45 Here, we demonstrated a protective role of IL-33 in mouse experimental AAAs. Administration of exogenous IL-33 or overexpression of IL-33 using IL-33 transgenic mice attenuated AAA development in 2 independent mouse AAA models: CaPO 4 -ignited periaortic injury-induced and aortic elastase exposure-induced AAAs. Therefore, like in other cardiovascular diseases, IL-33 acted as an anti-inflammatory cytokine in AAA pathogenesis. Both CaPO 4 and elastase caused damages to the aortas and induced IL-33 production. Such postinjury induction of IL-33 may act as a protective signal to the aorta. In mouse CaPO 4 -induced AAA lesions, we detected elevated IL-33 expression in the adventitia fibroblasts. This observation may explain why periaortic fibroblasts slowed the development of mouse experimental AAA. In addition to release matrix elastase inhibitors as reported previously, 46 fibroblasts may also release IL-33 to slow AAA development, although our study did not provide direct evidence to support this hypothesis.
Tregs-a subpopulation of CD4 + T lymphocytes with immunosuppressive activity-are involved in the regulation of multiple diseases, such as autoimmunity, inflammation, and cardiovascular diseases. Recently, a number of studies confirmed that Tregs regulate the pathogenesis of AAA. [38] [39] [40] [41] 47 Analyses of the peripheral blood of patients with AAA showed a reduced frequency of CD4 + CD25 + T cells accompanied by decreased expression of Foxp3 and impaired immunosuppressive activity of Tregs in patients with AAA. 47 Treg depletion by anti-CD25 antibodies or genetic disruption of CD80/ CD86 aggravated the development of angiotensin-II-induced AAA. 39 Adoptive transfer or endogenous expansion of Tregs prevented AAA formation. 40 All these studies identified a protective role for Tregs on AAA and suggested that targeting Tregs may become a potential treatment of AAA. In this study, we demonstrated that Tregs from IL-33-treated mice showed much greater activity in suppressing SMC production of IL-6 and MCP-1 and macrophage expression of MMP-2/9 than control Tregs. Although not tested in this study, Tregs are known to suppress T-cell activation and proliferation. 48 IL-33-expanded Tregs exhibited elevated immunosuppressive capacity against the proliferation of CD4 + and CD8 + T cells. 49 The activities of IL-33-treated Tregs in reducing vascular cell expression of MCP-1 and possibly other untested chemokines and in regulating T-cell activation and proliferation may all contribute to the reduced AAA lesion CD3 + T cells and CD68 + macrophages that we detected from IL-33-treated mice. Macrophages exist in different phenotypes in the innate immune system, including the proinflammatory M1 phenotype and the anti-inflammatory M2 phenotype.
50 M1 macrophages were increased in human and mouse models of AAA. Adoptive transfer of M2 macrophages preserved arterial wall elastica. 51 Here, we found that IL-33 increased M2-type macrophages and associated gene expression but reduced M1-type macrophages and their gene expression in AAA lesions. We also demonstrated that IL-33-expanded Tregs had much greater activity to induce the M1-to-M2 switch than control Tregs. Using ST2-deficient mice and Treg-depleted DEREG mice, we report that IL-33 protected mice from AAA development by inducing ST2-dependent Treg proliferation. IL-33 failed to induce Treg expansion in ST2-deficient mice and lost its AAA-protective activity in Treg-depleted DEREG mice. Although we proposed the hypothesis that IL-33 may act directly on the ST2 on Tregs and affect Treg biology, it is possible that IL-33 may affect Treg biology indirectly. Recent study by Molofsky et al 13 indicated that IL-33-activated type 2 innate lymphoid cells also induced Treg accumulation through the interactions between Treg ICOS (inducible co-stimulator) and type 2 innate lymphoid cells ICOSL (inducible co-stimulator ligand). Morita et al 52 reported that IL-33 promoted
Treg expansion by stimulating mast cells to produce IL-2. These prior studies suggest that IL-33 may also use type 2 innate lymphoid cells, mast cells, and other unidentified cells to affect Treg proliferation and immunosuppressive activity to block AAA development-a possibility that merits further investigation. Together, our study provided evidence from 2 experimental AAA models that IL-33 plays a protective role in attenuating AAA growth by controlling Treg proliferation and its immunosuppressive activities. Recombinant IL-33 or regimens to increase endogenous IL-33 expression may restrict the progression of mature AAA or prevent human AAA development.
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